Precancer抗病毒治疗可减少早期乙型肝炎相关肝细胞癌的微血

StephenW

Sci Rep. 2019 Feb 18;9(1):2220. doi: 10.1038/s41598-019-39440-7.
Precancer antiviral treatment reduces microvascular invasion of early-stage Hepatitis B-related hepatocellular carcinoma.
Liu K1, Duan J1, Liu H1, Yang X1, Yang J1, Wu M1, Chang Y2.
Author information

1
    Department of Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, 200438, PR China.
2
    Department of Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, 200438, PR China. [email protected].

Abstract

The impact of antiviral therapy before tumorigenesis on microvascular invasion (MVI) of Chronic hepatitis B (CHB)-related hepatocellular carcinoma (HCC) is still unknown. In this retrospective cohort study 3,276 HCC patients with early-stage who underwent curative resection were included. We investigated the effect of precancer antiviral therapy on the pathology, especially MVI, of CHB-related HCC. MVI occurrence rates of CHB-related HCC stratified by histopathologic inflammation grades of G1, G2, and G3 were 30.4%, 34.7%, and 38.6%, respectively, compared to 19.8% for CHB-negative HCC. Patients who received standard antiviral treatment showed much lower rates of MVI, higher tumor capsule integrity, less frequent satellite micronodules and lower AFP level compared to the no antiviral group. Moreover, precancer antiviral therapy prolonged the disease-free survival (DFS), which are also proved to be independent indicators of DFS. In addition, we show that antivirals may suppress early progression of HCC primarily by inhibition of HBV viral load, and influencing the expression levels of CK18, GPC3, OPN and pERK. Hence, we demonstrate that precancer antivirals significantly reduce the MVI rate of CHB-related HCC, reduce malignancy of early-stage HCC, and improve HCC prognosis. Thus, this study confirms the importance of antiviral therapy for CHB patients.

PMID:
    30778112
DOI:
    10.1038/s41598-019-39440-7

StephenW

Sci Rep.20119 Feb 18; 9（1）：2220。 doi：10.1038 / s41598-019-39440-7。
Precancer抗病毒治疗可减少早期乙型肝炎相关肝细胞癌的微血管侵犯。
Liu K1，段J1，刘H1，杨X1，杨J1，吴M1，张Y2。
作者信息

1
    第二军医大学东方肝胆外科医院外科，上海，200438。
2
    第二军医大学东方肝胆外科医院外科，上海，200438。 [email protected]。

抽象

肿瘤发生前抗病毒治疗对慢性乙型肝炎（CHB）相关性肝细胞癌（HCC）微血管侵犯（MVI）的影响尚不清楚。在这项回顾性队列研究中，纳入了3,276例早期接受根治性切除术的HCC患者。我们研究了癌前病变抗病毒治疗对CHB相关HCC病理学特别是MVI的影响。由组织病理学炎症分级G1，G2和G3分层的CHB相关HCC的MVI发生率分别为30.4％，34.7％和38.6％，而CHB阴性HCC为19.8％。接受标准抗病毒治疗的患者与无抗病毒治疗组相比，MVI发生率低，肿瘤囊完整性更高，卫星微小结节更少，AFP水平更低。此外，癌症前抗病毒治疗延长了无病生存期（DFS），这也被证明是DFS的独立指标。此外，我们表明抗病毒药物可能主要通过抑制HBV病毒载量和影响CK18，GPC3，OPN和pERK的表达水平来抑制HCC的早期进展。因此，我们证明了癌前病毒抗体显着降低了CHB相关HCC的MVI率，降低了早期HCC的恶性程度，并改善了HCC的预后。因此，该研究证实了抗病毒治疗对CHB患者的重要性。

结论：
    30778112
DOI：
    10.1038 / s41598-019-39440-7